Science Explorer Back to mapMap
Discussion
Researcher · Merck KGaA, Darmstadt (Germany) · Germany

Frank T. Zenke

Frank T. Zenke publishes mostly in Molecular Biology, Oncology and Cell Biology, on topics such as DNA Repair Mechanisms, PARP inhibition in cancer therapy and Cancer therapeutics and mechanisms.

ORCID 0000-0002-2226-3755 OpenAlex
World rank
#270,234
of 7,710,434 ranked researchers
Rank in Germany
#13,645
of 364,343
Works
356
Citations
4.1k
Citations per work
11.5
h-index
28
i10-index 52Top 17% in Molecular Biology
Frank T. Zenke

What does Frank T. Zenke research?

Frank T. Zenke's work is mostly in Biochemistry, Genetics and Molecular Biology (56%), Medicine (24%), Immunology and Microbiology (4%).

Life Sciences: 213 works · 59.8% of their workBiochemistry, Genetics and Molecular Biology: 200 works · 56.2% of their workMolecular Biology: 171 works · 48.1% of their workCell Biology: 16 works · 4.5% of their workCancer Research: 13 works · 3.6% of their workImmunology and Microbiology: 13 works · 3.6% of their workImmunology: 13 works · 3.6% of their workHealth Sciences: 87 works · 24.3% of their workMedicine: 87 works · 24.3% of their workOncology: 76 works · 21.4% of their workPulmonary and Respiratory Medicine: 10 works · 2.9% of their workEverything else: 57 works · 15.9% of their workTHEIR WORKFrank T. Zenke356works
Life Sciences60%Health Sciences24%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology20056.2%
    2. Immunology and Microbiology133.6%
    1. Medicine8724.3%
  3. Everything else5715.9%
  1. 1Molecular Biology48% of their works
  2. 2Oncology21% of their works
  3. 3Cell Biology4% of their works
  4. 4Cancer Research4% of their works
  5. 5Immunology4% of their works
  6. 6Pulmonary and Respiratory Medicine3% of their works

Research topics

Which keywords describe Frank T. Zenke's research?

The keywords of their largest research topics: Cancer Therapy, Homologous Recombination, DNA Damage, Repair, Cell Death, Apoptosis, BRCA Mutation and PARP Inhibitors.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 20 words, with their numbers
  1. Cancer Therapy715 topics
  2. Homologous Recombination702 topics
  3. DNA Damage451 topic
  4. Repair451 topic
  5. Cell Death362 topics
  6. Apoptosis282 topics
  7. BRCA Mutation251 topic
  8. PARP Inhibitors251 topic
  9. DNA201 topic
  10. Topoisomerases201 topic
  11. Cell Cycle171 topic
  12. p53171 topic
  13. Bcl-2 Family111 topic
  14. Mitochondria111 topic
  15. Cell Division91 topic
  16. Innate Immunity91 topic
  17. Microtubules91 topic
  18. Proteasome91 topic
  19. Ubiquitin91 topic
  20. Viral Infection91 topic

Where does Frank T. Zenke work?

Frank T. Zenke's main affiliation in the publication record is Merck KGaA, Darmstadt (Germany), Germany.

How many publications and citations does Frank T. Zenke have?

OpenAlex counts 356 works and 4,094 citations for Frank T. Zenke, an h-index of 28, ranking #270,234 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Frank T. Zenke. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.